Should statin guidelines consider patient preferences? Eliciting preferences of benefit and harm outcomes of statins for primary prevention of cardiovascular disease in the sub-Saharan African and European contexts

Lignende værker

• Net benefit of statins for primary prevention of cardiovascular disease in people 75 years or older: a benefit–harm balance modeling study
  af: Yebyo, Henock G., et al.
  Udgivet: (2019)
• Global variation of risk thresholds for initiating statins for primary prevention of cardiovascular disease: a benefit-harm balance modelling study
  af: Yebyo, Henock G., et al.
  Udgivet: (2020)
• Benefit-harm analysis and charts for individualized and preference-sensitive prevention: example of low dose aspirin for primary prevention of cardiovascular disease and cancer
  af: Puhan, Milo A., et al.
  Udgivet: (2015)
• Balance of benefits and harms of different blood pressure targets in people with multiple chronic conditions: a quantitative benefit-harm assessment
  af: Aschmann, Hélène E, et al.
  Udgivet: (2019)
• Aspirin for Primary Prevention of Cardiovascular Disease and Cancer. A Benefit and Harm Analysis
  af: Stegeman, Inge, et al.
  Udgivet: (2015)